Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (101-110 of 198) with videos related to

Pageof 20
Sort By:
Cancer Chemotherapy and Pharmacology|March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trialCarmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studiesCesare Gridelli, Paolo Maione, Alfonso Illiano, et al.
BMC Health Services Research|November 27, 2020
Clinical trials and drug cost savings for Italian health serviceFrancesca D'Ambrosio, Gianfranco De Feo, Gerardo Botti, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel MeetingFilippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
Pharmacogenomics|August 8, 2015
Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patientsRaffaella Pasquale, Francesca Fenizia, Riziero Esposito Abate, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Cancers|October 14, 2022
BRAF Inhibitors in Non-Small Cell Lung CancerVincenzo Sforza, Giuliano Palumbo, Priscilla Cascetta, et al.
Plos One|October 22, 2015
Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung AdenocarcinomaFederica Zito Marino, Giuseppina Liguori, Gabriella Aquino, et al.
Anticancer Research|April 30, 2016
Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern ItalyGaetano Rocco, Tommasangelo Petitti, Nicola Martucci, et al.
The Lancet. Oncology|May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) studyCesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
Pageof 20

Showing results (101-110 of 198) with videos related to

Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trialCarmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studiesCesare Gridelli, Paolo Maione, Alfonso Illiano, et al.
BMC Health Services Research|November 27, 2020
Clinical trials and drug cost savings for Italian health serviceFrancesca D'Ambrosio, Gianfranco De Feo, Gerardo Botti, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel MeetingFilippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
Pharmacogenomics|August 8, 2015
Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patientsRaffaella Pasquale, Francesca Fenizia, Riziero Esposito Abate, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Cancers|October 14, 2022
BRAF Inhibitors in Non-Small Cell Lung CancerVincenzo Sforza, Giuliano Palumbo, Priscilla Cascetta, et al.
Plos One|October 22, 2015
Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung AdenocarcinomaFederica Zito Marino, Giuseppina Liguori, Gabriella Aquino, et al.
Anticancer Research|April 30, 2016
Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern ItalyGaetano Rocco, Tommasangelo Petitti, Nicola Martucci, et al.
The Lancet. Oncology|May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) studyCesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
Pageof 20